Company Profile
Oncocross develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis. Its portfolio also includes OC101+OC111 for non-alcoholic steatohepatitis, OC201+OC202e for Inhibition of cancer metastasis, OC211, a Pan-KRAS Inhibitor, OC221, an immuno-oncology combination, OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy, and OC701 to treat atopic dermatitis.
The company is also developing OJP3101 for metabolic disease. Its portfolio also includes OJP3101 for Cardiovascular Disease, ODP9401 for metabolic disease, and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases. It has a collaboration agreement with various pharmaceutical companies, research institutes, and bio-techs. Founded in 2015, the company is based in Seoul, South Korea.